Recalls from Ascend Laboratories, LLC

• Ascend Laboratories Amlodipine and Olmesartan Medoxomil Tablets (opens in a new tab)
  Moderate risk, FDA, Oct 16, 2026, Drug dissolving problem
• Ascend Laboratories Dabigatran Etexilate Capsules (opens in a new tab)
  Low risk, FDA, Jul 24, 2026, Drug impurity
• Ascend Laboratories Amlodipine and Olmesartan Medoxomil Tablets (opens in a new tab)
  Moderate risk, FDA, Jul 17, 2026, Drug dissolving problem
• Ascend Laboratories Dabigatran Etexilate Capsules (opens in a new tab)
  Low risk, FDA, Jul 17, 2026, Drug impurity
• Ascend Laboratories Minocycline Hydrochloride Extended-Release Tablets (opens in a new tab)
  Moderate risk, FDA, Jun 10, 2026, Drug dissolving problem

Data: Recall Canary (opens in a new tab)